Stoke Therapeutics, Inc.·4

Apr 3, 4:19 PM ET

Nash Huw M. 4

4 · Stoke Therapeutics, Inc. · Filed Apr 3, 2024

Insider Transaction Report

Form 4
Period: 2024-04-01
Nash Huw M.
COO & CBO
Transactions
  • Exercise/Conversion

    Common Stock

    2024-04-01$0.40/sh+50,000$20,00061,329 total
  • Sale

    Common Stock

    2024-04-01$13.22/sh60,929$805,768400 total
  • Sale

    Common Stock

    2024-04-01$13.61/sh400$5,4440 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-04-0150,00096,000 total
    Exercise: $0.40Exp: 2026-02-11Common Stock (50,000 underlying)
Footnotes (3)
  • [F1]The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023.
  • [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.60 to $13.59 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The option is fully vested.

Documents

1 file
  • 4
    form4-04032024_080414.xmlPrimary